Thus, combining adoptive transfer of Nr2f6 CRISPR/Cas9 genetically modified T cells showed synergistic effects with both the established PD-L1 and the CTLA-4 checkpoint blockade to promote tumor regression and increase survival in a subcutaneous tumor mouse model. This evidence concerns the gene CD274 and neoplasm.